
### ü´† Heart Failure: Asymptomatic HFrEF (Stage B) Management

#### ‚úÖ True Statements
1. **Stage B heart failure** includes patients with **reduced left ventricular ejection fraction (‚â§40%)** and no symptoms.
2. Treatment of **stage B heart failure with reduced ejection fraction (HFrEF)** includes **angiotensin-converting enzyme (ACE) inhibitors** or **angiotensin receptor blockers (ARBs)** and **Œ≤-blockers**.
3. **ACE inhibitors** reduce **mortality**, **heart failure hospitalizations**, and **worsening of heart failure** in asymptomatic patients with **reduced ejection fraction after myocardial infarction (MI)**.
4. **Valsartan-sacubitril** has **not been studied** in patients with **stage B (asymptomatic) heart failure**.
5. **Nondihydropyridine calcium channel blockers** such as **diltiazem** and **verapamil** have **negative inotropic effects** and should **not be used** in patients with **reduced ejection fraction**.
6. **Guideline-directed therapy** in stage B HFrEF includes both a **Œ≤-blocker** and an **ACE inhibitor** or **ARB** if tolerated.
7. In patients with **ACE inhibitor‚Äìinduced cough**, an **ARB** should be used instead.
8. **Angioedema** is a potential side effect of both **ACE inhibitors** and **ARBs**, though less common with ARBs.
9. **Œ≤-Blockers** improve **left ventricular remodeling**, increase **ejection fraction**, and reduce **mortality and hospitalization** in HFrEF.
10. **Valsartan-sacubitril** should not be used within **36 hours** of the last dose of an **ACE inhibitor**.
11. **Valsartan-sacubitril** is **contraindicated** in patients with a **history of angioedema**.
12. **Calcium channel blockers** such as **amlodipine** and **felodipine** may be used in HFrEF patients with persistent hypertension but have shown **neither benefit nor harm**.
13. **Statins** should not be used routinely in patients with HFrEF without another accepted indication.
14. **Echocardiography** should be repeated **3 months** after initial assessment of new-onset HFrEF **after medical optimization**, but **not routinely** thereafter unless there is a **change in clinical status** or planned **device intervention**.

#### üí¨ Extra
1. Structural or hemodynamic abnormalities (e.g., reduced EF) without symptoms define stage B.
2. This reflects current American Heart Association (AHA)/American College of Cardiology (ACC) guidelines.
3. The benefit of ACE inhibitors is supported by trials in patients with reduced EF post-MI.
4. The benefit of valsartan-sacubitril is demonstrated only in symptomatic patients (stage C or D).
5. Their negative inotropic effects can worsen systolic dysfunction.
6. Both classes are foundational in preventing progression to symptomatic heart failure.
7. Cough affects up to 20% of ACE inhibitor users.
8. There are rare reports of ARB-induced angioedema.
9. Clinical benefits apply only to specific agents: **bisoprolol**, **carvedilol**, and **metoprolol succinate**.
10. This washout period reduces the risk of angioedema from ACE/ARNI overlap.
11. Even patients tolerant of ARBs may not safely receive ARNIs after prior angioedema.
12. They can be considered if other agents are maximized and BP control is still needed.
13. Clinical trials showed no added benefit of statins in HFrEF patients without another indication (e.g., atherosclerotic cardiovascular disease).
14. Surveillance echocardiography is discouraged in clinically stable patients.

#### üìá Tags
#HeartFailure #HFrEF #StageB #ACEInhibitor #ARB #BetaBlocker #ValsartanSacubitril #Echocardiography #Cardiology

#### üìö Reference
Bergamasco A, Luyet-D√©ruaz A, Gollop ND, et al. Epidemiology of asymptomatic pre-heart failure: a systematic review. Curr Heart Fail Rep. 2022;19:146-156. PMID: 35355204 doi:10.1007/s11897-022-00542-5

#### üÜî Question ID
CVMCQ24089

#### üïí Last Updated
January 2025

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Heart Failure With Reduced Ejection Fraction

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. Treatment of **asymptomatic heart failure with reduced ejection fraction (stage B HFrEF)** includes **renin-angiotensin-aldosterone system (RAAS) inhibition** with an **ACE inhibitor** or **ARB**, and **Œ≤-blockade**.
2. In **symptomatic HFrEF**, initial therapy includes **angiotensin receptor‚Äìneprilysin inhibitors (ARNIs)** or **ACE inhibitors/ARBs**, **Œ≤-blockers**, **aldosterone antagonists**, and **sodium-glucose cotransporter-2 (SGLT2) inhibitors**.
3. **Valsartan-sacubitril** should be initiated **instead of ACE inhibitor/ARB** in symptomatic patients or used to **replace them** in those with **chronic symptomatic HFrEF (New York Heart Association [NYHA] class II-IV)** and **ejection fraction ‚â§40%**.
4. **Valsartan-sacubitril** should not be used in patients with **hypotension**, **history of angioedema**, or within **36 hours** of an ACE inhibitor.
5. **ACE inhibitors** and **ARBs** reduce **mortality and morbidity** in both symptomatic and asymptomatic patients with **HFrEF**, but ACE inhibitors have more evidence in asymptomatic patients.
6. **Œ≤-Blockers** should be one of **three agents** with proven mortality benefit (bisoprolol, carvedilol, metoprolol succinate).
7. **Œ≤-Blockers** are contraindicated in **acute decompensated heart failure**, **cardiogenic shock**, and **high-grade atrioventricular block**.
8. **SGLT2 inhibitors** improve **heart failure outcomes** and are indicated for **all patients with HFrEF** regardless of type 2 diabetes status.
9. **Calcium channel blockers** verapamil and diltiazem are **detrimental** in patients with **HFrEF** due to **negative inotropic effects**.
10. **Echocardiography** should be repeated after **optimization of therapy** but is not routinely indicated unless **clinical status changes**.
11. **ACE inhibitors** should be used with caution or not initiated if **serum creatinine >2.5 mg/dL** or **estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m¬≤**.
12. **Valsartan-sacubitril** should be avoided in patients with **systolic blood pressure <100 mm Hg**.
13. **Œ≤-Blockers** should be initiated **before hospital discharge** in stable patients with heart failure.
14. **Aldosterone antagonists** are **not a form of diuretic therapy** and should not be used to treat **volume overload**.
15. **Eplerenone** causes less **gynecomastia** and **breast tenderness** than **spironolactone**.
16. **SGLT2 inhibitors** are contraindicated in patients with **type 1 diabetes** or **prior diabetic ketoacidosis**.
17. **Loop diuretics** should be dosed at the **lowest dose necessary to achieve euvolemia**.
18. **Thiazide diuretics** should be administered **30 minutes before loop diuretics** when used together to potentiate diuresis.
19. **Digoxin** reduces **heart failure hospitalization** but **does not reduce mortality**.
20. **Digoxin toxicity** is more likely in **older adults**, **women**, and those with **kidney impairment**.
21. **Implantable cardioverter-defibrillator (ICD)** placement should be delayed **40 days after MI** or **3 months in non-MI cases** to allow time for **ejection fraction recovery**.
22. **Sleep-disordered breathing** is **underdiagnosed** in patients with **heart failure**.
23. **Central sleep apnea** treated with **adaptive servoventilation** in patients with **ejection fraction <45%** increases **mortality risk**.
24. **Sodium restriction (<1.5 g/d)** and **fluid restriction (1.5‚Äì2 L/d)** are commonly recommended for heart failure but have **limited supporting evidence**.
25. **Daily weight monitoring** is recommended to identify **early signs of heart failure decompensation**.
26. **Multidisciplinary team management** of heart failure is essential, especially at the time of **hospital discharge**.
27. **Nonjudgmental adherence evaluation** and **repeated patient education** are essential in chronic heart failure care.
28. Use of **nonsteroidal anti-inflammatory drugs (NSAIDs)** can **worsen heart failure** and **increase blood pressure**.
29. **Rapid up-titration** of **guideline-directed medical therapy** (all four classes) is preferred, followed by **outpatient optimization**.
30. **Patients with improved ejection fraction** should **continue all medical therapies** that led to improvement.
31. **Vericiguat** has a **class 2b recommendation** in HFrEF and reduced all-cause death or hospitalization in the **VICTORIA trial**.
32. Clinical indicators of **poor prognosis** in heart failure include **multiple hospitalizations**, **poor exercise tolerance**, **hyponatremia**, and **recurrent ICD discharges**.
33. **Heart failure hospitalization** carries a **10‚Äì20% mortality rate** in the **6 months following discharge**.
34. **Palliative care or hospice** should be considered in patients who are **not candidates for advanced therapies** like **left ventricular assist devices (LVADs)** or **transplant**.
41. The **target dose of carvedilol** in heart failure with reduced ejection fraction is **25 mg twice daily**, or **50 mg twice daily** if weight is **>85 kg (187 lb)**.
42. The **target dose of metoprolol succinate** in heart failure with reduced ejection fraction is **200 mg daily**.
43. The **target dose of bisoprolol** in heart failure with reduced ejection fraction is **10 mg daily**.
44. **Metformin** provides a **survival benefit** in patients with heart failure.
45. **Pioglitazone** is **not recommended** in patients with heart failure due to the risk of **worsening heart failure**.
46. **SGLT2 inhibitors** reduce the risk of **worsening heart failure** and **cardiovascular death**, regardless of diabetes status.
47. **GLP-1 receptor agonists** reduce **major adverse cardiovascular events** but have **no proven benefit or harm** in heart failure.
48. **DPP-4 inhibitors** have **no evidence of cardiovascular benefit** in patients with heart failure.
49. **Sulfonylureas** have **no randomized data** supporting their use in heart failure.
50. **Insulin** may be associated with **increased risk of heart failure**, based on observational studies.
51. Implantable cardioverter-defibrillators (ICDs) are indicated **‚â•40 days after myocardial infarction** in patients with **ejection fraction ‚â§30%** and **NYHA class I symptoms**.
52. **Cardiac resynchronization therapy (CRT)** is **not indicated** for patients with **NYHA class I symptoms**, even with low ejection fraction.
53. CRT is indicated in patients with **NYHA class II-IV symptoms**, **ejection fraction ‚â§35%**, **sinus rhythm**, and **left bundle branch block (LBBB)** with a **QRS duration ‚â•150 ms**.
54. ICD and CRT therapies require patients to be on **maximally tolerated heart failure medications** and to have a **life expectancy of at least 1 year**.

#### üí¨ Extra
1. These are the only two drug classes currently endorsed for stage B therapy.
2. These therapies are supported by guideline-directed algorithms for symptomatic patients (stage C or D).
3. Valsartan-sacubitril has demonstrated benefit in symptomatic patients in the PARADIGM-HF trial.
4. Safety concerns with valsartan-sacubitril include hypotension and risk of angioedema.
5. ACE inhibitors block angiotensin II formation, ARBs block its receptor; both reduce afterload and fibrosis.
6. These agents uniquely demonstrated mortality benefit in randomized trials.
7. Initiating during decompensation may worsen heart failure symptoms.
8. Trials show benefit independent of glucose-lowering effect; renal thresholds apply for use.
9. These agents worsen systolic function and are contraindicated in HFrEF.
10. Routine imaging is not necessary unless guiding device decisions or assessing new symptoms.
11. This threshold reflects common nephrology and cardiology practice to avoid worsening renal function.
12. Hypotension risk is increased due to neprilysin inhibition.
13. Hospital initiation ensures tolerability and smoother outpatient titration.
14. Aldosterone antagonists are for neurohormonal blockade, not diuresis.
15. This is due to eplerenone‚Äôs higher receptor selectivity.
16. Ketoacidosis risk makes SGLT2 inhibitors unsafe in these populations.
17. Higher doses may worsen electrolyte imbalances without added benefit.
18. This timing enhances synergistic action on nephron segments.
19. It is often used for rate control in atrial fibrillation with HFrEF.
20. Renal clearance and volume distribution affect toxicity thresholds.
21. Early ICD placement may be unnecessary if EF improves.
22. Screening improves quality of life and management.
23. Increased mortality with adaptive servoventilation was shown in clinical trials.
24. Lifestyle modification is low-risk, but evidence of outcome impact is weak.
25. Sudden weight gain can signal fluid retention before symptom onset.
26. Medication education and caregiver planning are key elements at discharge.
27. Identifying barriers (e.g., cost, cognition) improves compliance.
28. NSAIDs antagonize diuretic effect and promote fluid retention.
29. Initiating all four pillars early maximizes mortality and hospitalization benefit.
30. Regression of EF does not equate to cured disease; relapse risk remains.
31. The trial showed a 3% absolute risk reduction in the composite outcome.
32. These factors signal end-stage disease requiring specialist input.
33. Readmission is common and carries significant prognostic weight.
34. Prognostic awareness can guide shared decision-making and end-of-life care.
41. The higher 50 mg twice daily dose of carvedilol is recommended for patients weighing over 85 kg (187 lb), based on heart failure dosing guidelines.
42. The 200 mg daily dose of metoprolol succinate reflects the maximum studied in major trials that demonstrated benefit in HFrEF.
43. The 10 mg daily target dose for bisoprolol was used in the CIBIS-II trial, which showed reduced mortality in HFrEF.
44. Metformin is beneficial unless contraindicated, such as in patients with lactic acidosis risk or hemodynamic instability (e.g., cardiogenic shock).
45. Pioglitazone increases fluid retention and the risk of decompensated heart failure, especially in NYHA class II-IV.
46. SGLT2 inhibitors demonstrated benefit in patients with HFrEF and HFpEF regardless of diabetes status in the DAPA-HF and EMPEROR trials.
47. GLP-1 receptor agonists reduce atherosclerotic events, but clinical trials in HF patients have shown no clear benefit or harm.
48. DPP-4 inhibitors, particularly saxagliptin, have been linked to increased HF hospitalizations in some studies, prompting caution.
49. Sulfonylureas are commonly used in diabetes management but lack randomized trial data supporting efficacy or safety in heart failure.
50. Insulin may worsen heart failure through mechanisms such as fluid retention, weight gain, and neurohormonal activation.
51. A waiting period of at least 40 days post-MI is recommended before ICD placement to allow reassessment of ejection fraction, as some patients recover.
52. CRT is not indicated in NYHA class I because evidence shows little benefit without symptomatic heart failure, even with reduced EF.
53. CRT is most effective in symptomatic HFrEF patients with sinus rhythm, LBBB, EF ‚â§35%, and QRS ‚â•150 ms, where it improves synchrony and outcomes.
54. Guidelines stipulate that CRT and ICD should only be used in patients on maximally tolerated heart failure therapy with an anticipated survival of at least 1 year.

#### üè∑Ô∏è Tags
#StageBHeartFailure #HFrEF #ACEInhibitor #ARB #BetaBlocker #ARNI #SGLT2Inhibitor #CalciumChannelBlocker #Echocardiography #HeartFailureGuidelines #HeartFailurePrognosis #HeartFailureDevices #LVAD #ICD #NSAIDs #MultidisciplinaryCare #DailyWeights #Digoxin #CardiacRehab #AdvancedTherapies #SleepApnea #Vericiguat

---

#### üßæ Supplemental Tables

<!-- Œ≤-blocker Table -->
<table>
  <caption><strong>Therapeutic Dosages of Œ≤-Blockers for Treatment of Heart Failure With Reduced Ejection Fraction</strong></caption>
  <thead><tr><th>Agent</th><th>Target Dosage</th></tr></thead>
  <tbody>
    <tr><td>Carvedilol</td><td>25 mg twice daily (50 mg twice daily if weight &gt;85 kg [187 lb])</td></tr>
    <tr><td>Metoprolol succinate</td><td>200 mg daily</td></tr>
    <tr><td>Bisoprolol</td><td>10 mg daily</td></tr>
  </tbody>
</table>

<!-- Glucose-Lowering Medications in Patients With Heart Failure -->
<table border="1" cellpadding="6" cellspacing="0" style="border-collapse:collapse; width:100%; max-width:800px;">
  <caption style="font-weight:bold; text-align:left; padding-bottom:8px;">
    Glucose-Lowering Medications in Patients With Heart Failure
  </caption>
  <thead style="background-color:#f0f0f0;">
    <tr>
      <th style="text-align:left;">Drug Class</th>
      <th style="text-align:left;">Common Drugs</th>
      <th style="text-align:left;">Considerations</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Biguanides</td>
      <td>Metformin</td>
      <td>
        Survival benefit in patients with HF<br>
        Discontinue in patients with lactic acidosis&nbsp;or cardiogenic shock
      </td>
    </tr>
    <tr>
      <td>Sulfonylureas</td>
      <td>Glyburide, Glipizide, Glimepiride</td>
      <td>No randomized data in patients with HF</td>
    </tr>
    <tr>
      <td>Thiazolidinediones</td>
      <td>Pioglitazone</td>
      <td>Not recommended because of increased risk&nbsp;/ worsening of HF</td>
    </tr>
    <tr>
      <td>Insulin</td>
      <td>&mdash;</td>
      <td>Observational studies suggest an increase in HF with insulin therapy</td>
    </tr>
    <tr>
      <td>GLP-1 receptor agonists</td>
      <td>Dulaglutide, Exenatide, Liraglutide, Semaglutide</td>
      <td>
        Reduce major adverse cardiovascular events but no effect or detriment in patients with HF<br>
        If recent HF hospitalization, use with caution (based on two small trials)
      </td>
    </tr>
    <tr>
      <td>DPP-4 inhibitors</td>
      <td>Alogliptin, Linagliptin, Saxagliptin, Sitagliptin</td>
      <td>No evidence of cardiovascular benefit</td>
    </tr>
    <tr>
      <td>SGLT2 inhibitors</td>
      <td>Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin</td>
      <td>
        Reduce risk for worsening HF and cardiovascular death in patients with HFrEF or HFpEF with or without type 2 diabetes mellitus<br>
        Reduce cardiovascular deaths and HFpEF hospitalizations regardless of whether diabetes is present
      </td>
    </tr>
  </tbody>
</table>
<p style="font-size:0.9em; margin-top:8px;">
  <em>
    DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide 1; HF = heart failure;
    HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with
    reduced ejection fraction; SGLT2 = sodium-glucose cotransporter 2.
  </em>
</p>

<!-- NYHA Indications Table -->
<table>
  <caption><strong>NYHA Class I Indications for ICD and CRT</strong></caption>
  <thead>
    <tr>
      <th>NYHA Class</th>
      <th>ICD</th>
      <th>CRT</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>I</td>
      <td>‚â•40 d after MI<sup>b</sup>, EF ‚â§30%</td>
      <td>None</td>
    </tr>
    <tr>
      <td>II</td>
      <td>EF ‚â§35%</td>
      <td>EF ‚â§35%, sinus rhythm, LBBB with QRS ‚â•150 ms</td>
    </tr>
    <tr>
      <td>III</td>
      <td>EF ‚â§35%</td>
      <td>EF ‚â§35%, sinus rhythm, LBBB with QRS ‚â•150 ms</td>
    </tr>
    <tr>
      <td>IV</td>
      <td>Only for patients being considered for heart transplantation</td>
      <td>EF ‚â§35%, sinus rhythm, LBBB with QRS ‚â•150 ms</td>
    </tr>
  </tbody>
</table>

<p><em>
CRT = cardiac resynchronization therapy; EF = ejection fraction; ICD = implantable cardioverter-defibrillator; LBBB = left bundle branch block; MI = myocardial infarction; NYHA = New York Heart Association.<br>
aAll patients should be receiving maximally tolerated heart failure medications and have an anticipated survival of at least 1 year.<br>
bAfter MI, a waiting period of at least 40 days is required; for nonischemic myocardial injury, the waiting period is usually at least 3 months.
</em></p>

<!-- Cardiac Implantable Electronic Devices for Treatment of Cardiac Rhythm Disorders -->
<table>
  <caption><strong>Cardiac Implantable Electronic Devices for Treatment of Cardiac Rhythm Disorders</strong></caption>
  <thead>
    <tr>
      <th>Device</th>
      <th>Components</th>
      <th>Indications</th>
      <th>Pacemaker Function</th>
      <th>Antitachycardia Pacing</th>
      <th>Defibrillation</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Transvenous pacemaker</td>
      <td>Pulse generator and intravascular leads (single or dual chamber)</td>
      <td>Sinus node dysfunction, AV block, nonreversible symptomatic bradycardia</td>
      <td>Yes</td>
      <td>No</td>
      <td>No</td>
    </tr>
    <tr>
      <td>Leadless pacemaker</td>
      <td>Pulse generator implanted directly and entirely into the cardiac chamber; no leads</td>
      <td>Atrial fibrillation with bradycardia, paroxysmal bradycardia (e.g., brief sinus node dysfunction or AV block)</td>
      <td>Yes (atrial sensing and ventricular pacing)</td>
      <td>No</td>
      <td>No</td>
    </tr>
    <tr>
      <td>Implantable cardioverter-defibrillator</td>
      <td>Defibrillator and intravascular leads (single or dual chamber)</td>
      <td>Monitoring and treatment of ventricular arrhythmias</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>Yes</td>
    </tr>
    <tr>
      <td>Subcutaneous implantable cardioverter-defibrillator</td>
      <td>Defibrillator and a single lead that are entirely under the skin (extravascular and extrathoracic); no transvenous leads</td>
      <td>Monitoring and treatment of ventricular arrhythmias</td>
      <td>No</td>
      <td>No</td>
      <td>Yes</td>
    </tr>
    <tr>
      <td>Cardiac resynchronization therapy‚Äìpacing (CRT-P)</td>
      <td>Pulse generator and intravascular leads, including a pacing lead in the coronary sinus to pace the left ventricle</td>
      <td>Restoring electrical synchrony in select patients with symptomatic heart failure</td>
      <td>Yes</td>
      <td>No</td>
      <td>No</td>
    </tr>
    <tr>
      <td>Cardiac resynchronization therapy‚Äìdefibrillator (CRT-D)</td>
      <td>Defibrillator and intravascular leads, including a pacing lead in the coronary sinus to pace the left ventricle</td>
      <td>Restoring electrical synchrony between the ventricles in patients with heart failure; monitoring and treating ventricular arrhythmias</td>
      <td>Yes</td>
      <td>Yes</td>
      <td>Yes</td>
    </tr>
  </tbody>
</table>

<p><em>AV = atrioventricular.</em></p>


---

#### üñºÔ∏è Supplemental Figures

<figure>
  <img src="ACC Management of Heart Failure.svg" alt="ACC Management of Heart Failure">
  <figcaption>
    ACEi = ACE inhibitor; ARB = angiotensin receptor blocker; BP = blood pressure; CVD = cardiovascular disease; HF = heart failure; ICD = implantable cardioverter-defibrillator; LVEF = left ventricular ejection fraction; MI = myocardial infarction; SGLT2i = sodium-glucose cotransporter 2 inhibitor.<br>
    Reprinted from: Heidenreich PA et al. Circulation. 2022;145:e895-e1032. PMID: 35363499
  </figcaption>
</figure>

<figure>
  <img src="Treatment of Heart Failure With Reduced Ejection Fraction (HFrEF) Stages C and D.svg" alt="Treatment of HFrEF Stages C and D">
  <figcaption>
    Treatment recommendations for patients with heart failure with reduced ejection fraction (HFrEF) are displayed. Green indicates a class 1 (strong), yellow a class 2a (moderate), and orange a class 2b (weak) recommendation. Step 1 medications may be started simultaneously at initial (low) doses recommended for HFrEF. Alternatively, these medications may be started sequentially, with sequence guided by clinical or other factors, without the need to achieve target dosing before initiating the next medication. Medication doses should be increased to target as tolerated. Although current guidelines support the use of isosorbide dinitrate‚Äìhydralazine in Black patients, making management decisions on the basis of skin color is likely a flawed approach. Questions regarding the underlying studies and the appropriateness of using race to direct management are driving a reevaluation of these recommendations.<br>
    <strong>Abbreviations:</strong> ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNi = angiotensin receptor‚Äìneprilysin inhibitor; CRT = cardiac resynchronization therapy; GDMT = guideline-directed medical therapy; HF = heart failure; HFimpEF = heart failure with improved ejection fraction; hydral-nitrates = hydralazine and isosorbide dinitrate; ICD = implantable cardioverter-defibrillator; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MCS = mechanical circulatory support; MRA = mineralocorticoid receptor antagonist; NSR = normal sinus rhythm; NYHA = New York Heart Association; SGLT2i = sodium-glucose cotransporter 2 inhibitor.<br>
    <em>a</em> Participation in investigational studies is appropriate for stage C, NYHA class II and III HF.<br>
    <em>Reprinted from:</em> Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary. <em>J Am Coll Cardiol.</em> 2022. PMID: 35379504 doi:10.1016/j.jacc.2021.12.011. ¬©2022, with permission from Elsevier.
  </figcaption>
</figure>


